Neutrolis key facts
as of Oct 2026- Operator of a biotechnology company intended to develop therapeutics that target neutrophils, the most abundant immune cell in our body.
- Neutrolis is valued at approximately $76.6M as of Oct 2026, set at its later-stage round, Jul 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $48.0M across 3 recorded rounds; the latest was Seed Round ($3.5M) in Jun 2025.
- Notable investors include Morningside Group, Oceanpine Capital, First Rice Capital, LabCentral, PBJ Capital — 7 tracked in total.
- Neutrolis has filed 3 Form Ds with the SEC since 2021, most recently Jul 2025 ($3.5M sold to 1 investors).
- Status: Privately Held (backing).
Valued at $76.6M at its later-stage round, Jul 2025. Nothing has traded since.
- ·Watch Neutrolis: the Monday email on marks, rounds and moves
Neutrolis funding rounds
3 roundsNeutrolis valuation
Neutrolis was valued at $76.6 million at its later-stage round in Jul 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Neutrolis raised?
Neutrolis has raised $48 million across 3 recorded rounds since 2021. The largest was a $964,955 seed round in Feb 2025; the most recent was a $3.5 million seed round in Jun 2025.
Neutrolis has filed 3 Form Ds with the SEC since 2021, most recently in Jul 2025 ($3.5 million sold to 1 investor).
Neutrolis investors
7 investors are on record for Neutrolis, including Morningside Group, Oceanpine Capital, First Rice Capital and LabCentral. The seed round in Jun 2025 drew 1 investor.
About Neutrolis
Operator of a biotechnology company intended to develop therapeutics that target neutrophils, the most abundant immune cell in our body. The company utilizes its proprietary platform to power the creation of natural and engineered enzyme analogs that are capable of treating several acute and chronic unmet medical needs and that are optimized for use in therapy, enabling doctors to degrade NETs' biologically inactive fragments to attenuate a severe immune response.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2017
- Employees
- 9
- Website
- neutrolis.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.